A novel ITGA2B double cytosine frameshift variant (c.1986_1987insCC) leads to Glanzmann's thrombasthenia in a cat.
congenital
feline
glycoprotein IIb/IIIa
macrothrombocytopenia
precision medicine
thrombopathia
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
03
11
2023
accepted:
16
02
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
Glanzmann's thrombasthenia (GT) is a congenital platelet disorder affecting approximately 1:1 000 000 people globally and characterized by impaired platelet aggregation and clot retraction. Autosomal recessive, loss-of-function, variants in ITGA2B or ITGB3 of the αIIbβ3 receptor cause the disease in humans. A cat affected by Glanzmann's and macrothrombocytopenia was presented to the UC Davis VMTH. Severe thrombopathia in this cat has an underlying genetic etiology. A single affected patient, 2 age-matched clinically healthy controls, and a geriatric population (n = 20) of normal cats. Physical examination and clinical pathology tests were performed on the patient. Flow cytometry and platelet aggregometry analyses for patient phenotyping were performed. Patient and validation cohort gDNA samples were extracted for Sanger sequencing of a previously identified ITGA2B (c.1986delC) variant. Reverse transcriptase PCR was performed on patient and healthy control PRP samples to verify ITGA2B variant consequence. A novel c.1986_1987insCC autosomal recessive variant in ITGA2B was identified. This variant was absent in a population of 194 unrelated cats spanning 44 different breeds. Complete loss of ITGA2B transcript and protein expression was verified by RT-PCR and flow cytometry, explaining the underlying etiology of GT, and likely macrothrombocytopenia, in this cat. This study emphasizes the role of precision medicine in cardiovascular disease of cats and identified yet another variant that may be of utility for screening in the feline population. This study provides a small-volume, standardized, successful protocol for adequate platelet RNA isolation and subsequent molecular assessment of gene expression in cats.
Sections du résumé
BACKGROUND
BACKGROUND
Glanzmann's thrombasthenia (GT) is a congenital platelet disorder affecting approximately 1:1 000 000 people globally and characterized by impaired platelet aggregation and clot retraction. Autosomal recessive, loss-of-function, variants in ITGA2B or ITGB3 of the αIIbβ3 receptor cause the disease in humans. A cat affected by Glanzmann's and macrothrombocytopenia was presented to the UC Davis VMTH.
HYPOTHESIS/OBJECTIVES
OBJECTIVE
Severe thrombopathia in this cat has an underlying genetic etiology.
ANIMALS
METHODS
A single affected patient, 2 age-matched clinically healthy controls, and a geriatric population (n = 20) of normal cats.
METHODS
METHODS
Physical examination and clinical pathology tests were performed on the patient. Flow cytometry and platelet aggregometry analyses for patient phenotyping were performed. Patient and validation cohort gDNA samples were extracted for Sanger sequencing of a previously identified ITGA2B (c.1986delC) variant. Reverse transcriptase PCR was performed on patient and healthy control PRP samples to verify ITGA2B variant consequence.
RESULTS
RESULTS
A novel c.1986_1987insCC autosomal recessive variant in ITGA2B was identified. This variant was absent in a population of 194 unrelated cats spanning 44 different breeds. Complete loss of ITGA2B transcript and protein expression was verified by RT-PCR and flow cytometry, explaining the underlying etiology of GT, and likely macrothrombocytopenia, in this cat.
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
This study emphasizes the role of precision medicine in cardiovascular disease of cats and identified yet another variant that may be of utility for screening in the feline population. This study provides a small-volume, standardized, successful protocol for adequate platelet RNA isolation and subsequent molecular assessment of gene expression in cats.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : HL086350
Pays : United States
Organisme : NCATS NIH HHS
ID : TR001861
Pays : United States
Informations de copyright
© 2024 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Références
Palma-Barqueros V, Revilla N, Sánchez A, et al. Inherited platelet disorders: an updated overview. Int J Mol Sci. 2021;22(9):4521. doi:10.3390/ijms22094521
Bastida JM, Benito R, Lozano ML, et al. Molecular diagnosis of inherited coagulation and bleeding disorders. Semin Thromb Hemost. 2019;45(7):695-707. doi:10.1055/s-0039-1687889
Oved JH, Lambert MP, Kowalska MA, Poncz M, Karczewski KJ. Population based frequency of naturally occurring loss-of-function variants in genes associated with platelet disorders. J Thromb Haemost. 2021;19(1):248-254. doi:10.1111/jth.15113
Botero JP, Lee K, Branchford BR, et al. Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica. 2020;105(4):888-894. doi:10.3324/haematol.2018.214239
Kannan M, Ahmad F, Yadav BK, Kumar R, Choudhry VP, Saxena R. Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia. J Thromb Haemost. 2009;7(11):1878-1885. doi:10.1111/j.1538-7836.2009.03579.x
Boudreaux MK, Catalfamo JL. Molecular and genetic basis for thrombasthenic thrombopathia in otterhounds. Am J Vet Res. 2001;62(11):1797-1804. doi:10.2460/ajvr.2001.62.1797
Lipscomb DL, Bourne C, Boudreaux MK. Two genetic defects in alphaIIb are associated with type I Glanzmann's thrombasthenia in a Great Pyrenees dog: a 14-base insertion in exon 13 and a splicing defect of intron 13. Vet Pathol. 2000;37(6):581-588. doi:10.1354/vp.37-6-581
Haysom LZ, Kennerly RM, Muller RD, Smith-Carr S, Christopherson PW, Boudreaux MK. Identification and characterization of Glanzmann thrombasthenia in 2 closely related mixed-breed dogs. J Vet Intern Med. 2016;30(2):642-646. doi:10.1111/jvim.13825
Li RHL, Ontiveros E, Nguyen N, et al. Precision medicine identifies a pathogenic variant of the ITGA2B gene responsible for Glanzmann's thrombasthenia in a cat. J Vet Intern Med. 2020;34(6):2438-2446. doi:10.1111/jvim.15886
Percie du Sert N, Ahluwalia A, Alam S, et al. Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 2020;18(7):e3000411. doi:10.1371/journal.pbio.3000411
Botsch V, Kuchenhoff H, Hartmann K, Hirschberger J. Retrospective study of 871 dogs with thrombocytopenia. Vet Rec. 2009;164(21):647-651. doi:10.1136/vr.164.21.647
Grindem CB, Breitschwerdt EB, Corbett WT, Jans HE. Epidemiologic survey of thrombocytopenia in dogs: a report on 987 cases. Vet Clin Pathol. 1991;20(2):38-43. doi:10.1111/j.1939-165x.1991.tb00566.x
Lipscomb DL, Bourne C, Boudreaux MK. Nucleotide sequence of the canine alphaIIb gene from platelet-derived cDNA. Am J Vet Res. 2001;62(9):1486-1492. doi:10.2460/ajvr.2001.62.1486
Nurden AT, Nurden P. Inherited thrombocytopenias: history, advances and perspectives. Haematologica. 2020;105(8):2004-2019. doi:10.3324/haematol.2019.233197
Huang J, Li X, Shi X, et al. Platelet integrin alphaIIbbeta3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol. 2019;12(1):26. doi:10.1186/s13045-019-0709-6
Bennett JS. The molecular biology of platelet membrane proteins. Semin Hematol. 1990;27(2):186-204.
Saboor M, Ayub Q, Ilyas S, Moinuddin. Platelet receptors; an instrumental of platelet physiology. Pak J Med Sci. 2013;29(3):891-896. doi:10.12669/pjms.293.3497
Estevez B, Shen B, Du X. Targeting integrin and integrin signaling in treating thrombosis. Arterioscler Thromb Vasc Biol. 2015;35(1):24-29. doi:10.1161/ATVBAHA.114.303411
Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673-687. doi:10.1016/s0092-8674(02)00971-6
Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol. 2010;11(4):288-300. doi:10.1038/nrm2871
Asch E, Podack E. Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin Invest. 1990;85(5):1372-1378. doi:10.1172/JCI114581
Fang J, Jensen ES, Boudreaux MK, et al. Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci U S A. 2011;108(23):9583-9588. doi:10.1073/pnas.1016394108
Fang J, Hodivala-Dilke K, Johnson BD, et al. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood. 2005;106(8):2671-2679. doi:10.1182/blood-2004-12-4619
Larson MK, Watson SP. Regulation of proplatelet formation and platelet release by integrin alpha IIb beta3. Blood. 2006;108(5):1509-1514. doi:10.1182/blood-2005-11-011957
Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103(2):229-238. doi:10.1172/JCI5487
Tronik-Le Roux D, Roullot V, Poujol C, Kortulewski T, Nurden P, Marguerie G. Thrombasthenic mice generated by replacement of the integrin alpha(IIb) gene: demonstration that transcriptional activation of this megakaryocytic locus precedes lineage commitment. Blood. 2000;96(4):1399-1408.
Kashiwagi H, Kunishima S, Kiyomizu K, et al. Demonstration of novel gain-of-function mutations of alphaIIbbeta3: association with macrothrombocytopenia and glanzmann thrombasthenia-like phenotype. Mol Genet Genomic Med. 2013;1(2):77-86. doi:10.1002/mgg3.9
Guillet B, Bayart S, Pillois X, Nurden P, Caen JP, Nurden AT. A Glanzmann thrombasthenia family associated with a TUBB1-related macrothrombocytopenia. J Thromb Haemost. 2019;17(12):2211-2215. doi:10.1111/jth.14622